rituximab,epcoritamab,lenalidomide
abbvie,genmab
['fil,veral,12', ' ev ', 'epcoritamab', 'emergent ']
congress | #ash22 , presents initial results from the phase i/ii trial of subcutaneous epcoritamab + r2 as first-line treatment for #fl. the combination demonstrated a manageable safety profile and encouraging efficacy, supporting further study 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm